

# Acute Care

# ISMP Medication Safety Alert!®

Educating the Healthcare Community About Safe Medication Practices

## Any new process poses a risk for errors: Learning from 4 months of COVID-19 vaccinations



**PROBLEM:** The Pfizer-BioNTech and Moderna mRNA coronavirus disease 2019 (COVID-19) vaccines were granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in mid-December 2020. Between December 14, 2020 (the date COVID-19 vaccinations began) and April 17, 2021, more than 107 million doses of the Pfizer-BioNTech vaccine and nearly 91 million doses of the Moderna vaccine had been administered in the US.<sup>1</sup> At the end of February, FDA granted EUA to a third COVID-19 vaccine, a human adenovirus viral vector vaccine from Janssen (Johnson & Johnson). As of April 13, 2021, nearly 8 million doses of the Janssen vaccine had been administered in the US.<sup>1</sup> Out of an abundance of caution, the Centers for Disease Control and Prevention (CDC) and FDA recommended pausing use of the Janssen vaccine on April 13, 2021, due to reports of a rare and severe type of blood clot (cerebral venous sinus thrombosis [CVST] with thrombocytopenia) in six women between the ages of 18 and 48, which occurred 6 to 13 days after receiving the Janssen vaccine.<sup>2,3</sup> CDC and FDA continue to investigate the potential role of the vaccine in this adverse event, especially since similar rare adverse events have been reported with the AstraZeneca COVID-19 vaccine, also an adenovirus (chimpanzee) viral vector vaccine, administered in Europe.<sup>4</sup>

In our January 14, 2021 newsletter, we published an analysis of the early vaccine errors we had received in the first month of administering the Pfizer-BioNTech and Moderna vaccines.<sup>5</sup> Now that the US has been administering COVID-19 vaccines for about 4 months, we have analyzed more than 160 COVID-19 vaccine errors voluntarily reported to ISMP between December 14, 2020, and April 15, 2021. The errors reported to ISMP do not reflect all COVID-19 vaccine errors that might be occurring nationally; in fact, the CDC has received more than 300 inquiries from practitioners seeking guidance for managing COVID-19 vaccine administration errors.<sup>6,7</sup> Because COVID-19 vaccine errors could result in reduced effectiveness, adverse drug events, and other safety implications, we want to share what we have learned about these errors and recommend best practices.

In our January analysis, most reports were associated with dilution errors (Pfizer-BioNTech vaccine), wasted vaccine doses, administration to the wrong age group, and errors associated with scheduling second doses.<sup>5</sup> While these error types continue to be reported, we are now receiving a wide variety of different error report types. During our analysis, each COVID-19 vaccine error report was categorized into one of four broad categories: general error types, errors specific to the two-dose vaccines, dilution errors with the Pfizer-BioNTech vaccine, and errors specific to the single-dose vaccine (**Table 1**, page 2). The following includes a description of each error type along with an example of a reported error. We conclude with safe practice recommendations to help prevent these types of errors. Please note: While ISMP has NOT received any reports of CVST or other adverse reactions to the Janssen vaccine, recommendations based on our analysis include best practices associated with a single-dose vaccine like the Janssen vaccine, despite its current pause in administration (which is expected to end soon).

### General Error Types with All Current FDA-Authorized COVID-19 Vaccines

Reports grouped into this general category predominately included error types associated with any of the FDA-authorized COVID-19 vaccines:

continued on page 2 — [COVID-19 vaccinations](#) >

## SAFETY briefs



### Problems with Guangdong Haiou syringes for COVID-19 vaccinations.

We have received several reports of safety mechanism-related malfunctions with the Guangdong Haiou Medical Apparatus Company syringes and needles that have been shipped by the federal government in some coronavirus disease 2019 (COVID-19) vaccine supply packs. One issue is that the needle/blue hub assembly (**Figure 1**) may retract into the syringe barrel, or the needle may detach from the syringe, during vaccine preparation when the vial is punctured or during vaccine administration when

continued on page 2 — [SAFETY briefs](#) >



**Figure 1.** Blue needle hub retracts into syringe barrel when the plunger is fully depressed during use.

## Customized ISMP consulting services

ISMP's nationally recognized experts are here to support you, even during the pandemic! Our interdisciplinary consulting team can offer medication safety solutions for healthcare facilities of all sizes and settings, virtually or in person. Whether you need assistance getting your medication safety program started, identifying potential issues, or solving ongoing problems, we can help. Our consulting team can provide you with an unbiased analysis of the medication-use process, a customized roadmap for improvement, and thoughtful guidance to help you significantly reduce and prevent medication errors in your organization. For more on services tailored for your specific needs, see the last page of the newsletter or visit: [www.ismp.org/node/23650](http://www.ismp.org/node/23650).

> **COVID-19 vaccinations** — continued from page 1

- **Administration of a dose lower than authorized**, often due to the patient pulling away during vaccination, leftover vaccine in the syringe after injection, or vaccine leakage during injection (e.g., premature retraction of a VanishPoint syringe needle, leakage with a Guangdong Haiou Medical Apparatus Company syringe—see a related **SAFETY** brief starting on page 1, right column)

*At a mass vaccination clinic, about 4,300 patients received 0.2 mL instead of 0.3 mL doses of the Pfizer-BioNTech vaccine. The orange-capped syringes from a national stockpile left about a third of the vaccine stuck in the bottom of the plastic syringe.<sup>8</sup>*

- **Administration to a patient younger than authorized** (less than 16 years for the Pfizer-BioNTech vaccine, less than 18 years for the Moderna and Janssen vaccines), often because the vaccine provider did not ask age-related screening questions

*Office staff were covering for a vaccine coordinator when a 16-year-old teen arrived with her mother, who wanted the teen immunized so she could visit a sick relative. The teen received the Moderna vaccine despite her unauthorized age.*

- **Administration using the wrong injection technique**, which often resulted in a shoulder injury related to vaccine administration (SIRVA)

continued on page 3 — **COVID-19 vaccinations** >

**Table 1.** Types and percentages of COVID-19 vaccine errors reported to ISMP (December 14, 2020, to April 15, 2021)

Error Type	Description/Examples	Percent (%) of Reports
<b>General Error Types with All Current FDA-Authorized COVID-19 Vaccines</b>		<b>62</b>
<b>Wrong Dose (Lower or Higher than Authorized)</b> (excludes dilution errors)	<ul style="list-style-type: none"> <li>■ Syringe/needle malfunction, spillage/leakage</li> <li>■ Dose measurement error</li> <li>■ Administration of an empty syringe of vaccine (air)</li> </ul>	20
<b>Wrong Age</b>	<ul style="list-style-type: none"> <li>■ Less than 16 years for the Pfizer-BioNTech vaccine</li> <li>■ Less than 18 years for the Moderna/Janssen vaccines</li> </ul>	17
<b>Wrong Administration Technique</b>	<ul style="list-style-type: none"> <li>■ Shoulder injury related to vaccine administration (SIRVA)</li> <li>■ Reuse of an empty syringe and needle</li> </ul>	8
<b>Wasted Vaccine</b> (excludes dilution errors)	<ul style="list-style-type: none"> <li>■ Leakage, contamination prior to administration</li> <li>■ Insufficient dose left in vial</li> </ul>	5
<b>Incorrect Storage and Handling</b>	<ul style="list-style-type: none"> <li>■ Temperature excursions outside of recommendations</li> <li>■ Administration of expired vaccine</li> </ul>	4
<b>Contraindicated Coadministration</b>	<ul style="list-style-type: none"> <li>■ Administration within 14 days of a non-COVID-19 vaccine</li> <li>■ Administration within 90 days of monoclonal antibodies</li> </ul>	2
<b>Other</b>	<ul style="list-style-type: none"> <li>■ Wrong needle size</li> <li>■ Other reasons for vaccine waste</li> <li>■ Wrong drug</li> </ul>	6
<b>Error Types Specific to the Two-Dose mRNA Vaccines (Moderna/Pfizer-BioNTech)</b>		<b>20</b>
<b>Mixed Vaccine Series</b>	<ul style="list-style-type: none"> <li>■ Incorrect mRNA vaccine administered for second dose</li> </ul>	11
<b>Wrong Time Interval</b>	<ul style="list-style-type: none"> <li>■ Second dose administered at the wrong interval</li> <li>■ Third dose administered</li> </ul>	9
<b>Dilution Errors Specific to the Pfizer-BioNTech Vaccine</b>		<b>17</b>
<b>Wrong Volume of Diluent</b>	<ul style="list-style-type: none"> <li>■ Too little diluent, leading to overdoses or waste</li> <li>■ Too much diluent, leading to underdoses or waste</li> <li>■ Diluted the vial twice</li> </ul>	11
<b>No Diluent</b>	<ul style="list-style-type: none"> <li>■ Administered undiluted vaccine</li> <li>■ “Diluted” vaccine with air in syringe thought to be diluent</li> </ul>	3
<b>Wrong Diluent</b>	<ul style="list-style-type: none"> <li>■ Sterile water used as diluent</li> </ul>	3
<b>Error Type Specific to the Single-Dose Viral Vector Vaccine (Janssen)</b>		<b>1</b>
<b>Confusing Vaccine Card</b>	<ul style="list-style-type: none"> <li>■ Two-dose vaccine cards shipped with single-dose vaccine</li> </ul>	1

> **SAFETY** briefs cont'd from page 1

the needle is still in the patient’s arm. It is important to remind staff to avoid fully depressing the syringe plunger when adding diluent or air to withdraw the solution from a vial, as this may prematurely engage the safety mechanism and result in the needle/hub becoming detached from the syringe tip to allow retraction inside the syringe barrel (as designed). The same problem can result when fully depressing the syringe plunger during injection, before the needle is removed from the patient’s arm. If the needle prematurely retracts into the syringe barrel, this can result in leaking vaccine around the syringe hub, potentially requiring revaccination. In other cases, it was reported that the syringe barrel may be punctured by the retracted needle if the plunger is advanced after the safety mechanism captures the needle/hub (**Figure 2**).



**Figure 2.** Needle can puncture through the syringe barrel if the plunger is advanced after the safety mechanism has been engaged.

Fully engaging the safety mechanism of the Haiou syringe is a multi-step process. After administration is complete and the needle has been withdrawn from the patient’s arm, the syringe plunger should be fully depressed to allow the safety mechanism to capture the needle/hub inside the syringe barrel. Next, users should fully retract the syringe plunger to the end of the syringe barrel and then snap off the syringe plunger to secure the needle/hub inside the syringe barrel prior to disposal.

Our affiliate organization, ECRI, does not recommend the purchase or use of the Haiou 1 mL Needle Retractable Safety Syringe because of these significant safety problems. If these syringes are found in COVID-19 supply packs shipped to your facility by the federal government, consider replacing the syringes with an alternative safety syringe. Please note that replacement syringes may be in short supply. For recommendations regarding the needle and syringe types to use for preparation and administration of COVID-19 vaccines, please visit: [www.ismp.org/ext/693](http://www.ismp.org/ext/693).

continued on page 3 — **SAFETY** briefs >

> **COVID-19 vaccinations** — continued from page 2

*A first responder received a vaccine too high in the shoulder from a volunteer nurse, leading to physician confirmation of SIRVA requiring possible surgical repair. The first responder's supervisor did not report the event to FDA. Five weeks later, the first responder is still in pain and has limited mobility of the arm or shoulder.*

Additional reports in this category included:

- Administration of a dose higher than authorized (e.g., 1 mL instead of 0.5 mL dose for the Moderna vaccine)
- Using the wrong needle size (e.g., needle length ¾ inch instead of 1 or 1.5 inches)
- Administration of an empty vaccine syringe (e.g., previously used syringe, sterile syringe with the plunger pulled back in preparation for vaccine or diluent withdrawal and air mistaken as vaccine)
- Incorrect vaccine storage and handling, leading to vaccine waste or administration of expired vaccine
- Other reasons for vaccine waste (e.g., inadvertent disposal, vaccine spillage)
- Administration of the wrong drug (e.g., **EPINEPHRINE** in a pharmacy-prepared syringe instead of a vaccine in a pharmacy-prepared syringe)
- Coadministration within 14 days of a non-COVID-19 vaccine and within 90 days of a monoclonal antibody used as part of a COVID-19 treatment

**Error Types Specific to the Two-Dose mRNA Vaccines (Moderna/Pfizer-BioNTech)**

Two error types were reported that were specific to the two-dose mRNA vaccines:

- **Administering the wrong mRNA vaccine for the second dose**, often due to scheduling patients to receive their second dose on days the site only administered one type of mRNA vaccine (which did not match the patient's first dose), or not verifying the manufacturer documented on the patient's vaccine card (or medical record or state/local immunization information system [IIS]) at the time of vaccination

*A patient received the Pfizer-BioNTech vaccine for the second dose instead of the Moderna vaccine. The vaccination site administered the different vaccines in two separate rooms. The patient joined the wrong line after checking in. The patient's vaccine card had been checked during the screening process but did not accompany the patient into the vaccination room. Prior to vaccination, the nurse did not believe she needed to verify the manufacturer since the patient had already been screened.*

- **Wrong interval errors** in which a second vaccine dose was administered too soon outside of the CDC-allowable 4-day grace period (less than 17 days [Pfizer-BioNTech] or 24 days [Moderna] after the first dose) or too late (more than 42 days after the first dose), or a third dose was inadvertently administered

*A second dose of the Moderna vaccine was administered 2 weeks early. The patient completed a questionnaire stating that she had not received a first dose of the vaccine. During a verbal interview, the patient did not say she had received the first Moderna vaccine dose 2 weeks earlier at a different facility and did not produce a vaccine card. The error was noticed when documenting vaccine administration in the state IIS. When the patient was called about the error, she said she had just answered "No" to all the questions without reading them.*

**Dilution Errors Specific to the Pfizer-BioNTech Vaccine**

Dilution errors related to the Pfizer-BioNTech vaccine were grouped into the following error-type categories:

- **Using the wrong volume of diluent**, including too little diluent, too much diluent, or diluting the vaccine vial twice


continued on page 4 — **COVID-19 vaccinations** >

> **SAFETY briefs** cont'd from page 2

**⚡ Ure-na, not hydroxyurea.** A one-time dose of hydroxyurea 500 mg was ordered for a renal patient. Since hydroxyurea is not normally prescribed as a one-time dose, and since the patient did not have a condition that was appropriate for the drug (certain cancers, sickle cell anemia), the pharmacist followed up with the prescriber. Good move! It turned out that **URE-NA** was the intended product. This is a palatable form of oral urea available in 15 g pouches used for the treatment of hyponatremia ([www.ismp.org/ext/675](http://www.ismp.org/ext/675)).

**⚡ Xylitol – toxic to dogs.** Please be aware of a potentially fatal toxicity specifically for dogs. The common sugar substitute xylitol can lead to a potent release of insulin in dogs, which can cause severe hypoglycemia, seizures, and liver failure. Canines are the only species in which xylitol is toxic. Xylitol is also a problem for dogs that need certain medications that might contain this product, including commercially available **NEURONTIN** (gabapentin) liquid medication commonly used for seizures in dogs. Make sure that pharmacists are aware that gabapentin for dogs must be compounded from tablets, without adding xylitol as a sweetener ([www.ismp.org/ext/587](http://www.ismp.org/ext/587)).

**⚡ Confusing syringe scale.** Staff or caregivers might be confused easily when measuring liquid medication doses using the syringe scale printed on Covidien's Monoject 3 mL enteral (ENFit) syringes. The scale is marked as ½, 1, ½, 2, ½, 3 mL (**Figure 1**). This can easily be misunderstood, reading the intended 1½ mL or 2½ mL as just ½ mL. The confusion could



lead to preparing and administering the wrong medication dose to a patient. We have let the company know the syringe scale should be revised as it is not safe to use. Syringe scales should never indicate doses using fractions but should indicate the entire volume using decimals (0.5, 1.5, 2.5). You may want to use an alternate syringe brand.

**Figure 1.** Syringe scale using fractions could easily confuse people, as 1½ mL or 2½ mL could be read as just ½ mL.

> **COVID-19 vaccinations** — continued from page 3

*A nurse diluted the same vaccine vial twice using 1.8 mL of 0.9% sodium chloride each time. She was distracted after the initial dilution. When she returned to the task, she picked up the same vial and diluted it again. She noticed the extra volume in the vial before administration. The vial of vaccine was discarded.*

■ **Using the wrong diluent**, mostly sterile water instead of 0.9% sodium chloride

*The Pfizer-BioNTech vaccine had been delivered to a hospital pharmacy, but the diluent remained in the truck that delivered the vaccine. A technician diluted the vaccine with sterile water, and the pharmacist who checked the diluent before it was added did not notice the error given the similarity of sterile water and 0.9% sodium chloride vials. Two doses were administered before the pharmacist noticed the error.*

■ **Not diluting the vaccine**, leading to administration of undiluted vaccine

*A nurse thought she had injected 1.8 mL of diluent into the vaccine vial. She withdrew the first dose of 0.3 mL and administered it, but the second dose was an insufficient volume. The nurse determined that air had been injected into the vaccine vial rather than the diluent.*

### Error Type Specific to the Single-Dose Viral Vector Vaccine (Janssen)

While we received numerous error reports associated with the Janssen vaccine that fall within the general category listed above, only one report was specifically related to a single-dose COVID-19 vaccine. As noted in a previous newsletter, current Vaccination Record Cards provided by the government include spaces to document two doses of the Moderna and Pfizer-BioNTech vaccines, along with a reminder to schedule the second dose.<sup>9</sup> This could cause confusion for patients receiving the single-dose Janssen vaccine. An update to the Vaccination Record Card for the single-dose vaccine is not being considered.

**SAFE PRACTICE RECOMMENDATIONS:** Millions of doses of the COVID-19 vaccines will be administered over the next few months. As we work toward expanding vaccinations to all, we must also learn from the vaccine errors that have already happened and implement strategies to minimize the risk of making these same vaccine errors. Consider the following targeted recommendations:

#### Staff competency

- Educate and orient all vaccination staff (including volunteers) regarding their role in COVID-19 vaccination check-ins, patient screening, preparation, and/or administration, as well as the common error types that may occur.
- Verify the competency of all vaccinators, particularly regarding:
  - Age indications for each vaccine
  - Proper dilution of only the Pfizer-BioNTech vaccine
  - Proper dose withdrawal technique
  - Appropriate injection site to prevent SIRVA ([www.ismp.org/node/21977](http://www.ismp.org/node/21977))
  - Timing and scheduling of a second vaccine dose (if needed)
- Verify the competency of all staff who check-in and screen patients for vaccination, particularly regarding:
  - Age indications for each vaccine
  - Timing and scheduling of a second vaccine dose (if needed)
  - Screening patients for allergies, prior vaccinations, prior administration of monoclonal antibodies used to treat COVID-19, and other health indicators
  - Verifying the first vaccine (date, manufacturer) via the state/local IIS, medical record, and/or the patient's vaccine card for patients requiring a second dose

#### Patient scheduling and check-in process

- Schedule patients for a second dose (if needed) before they leave the vaccination site after receiving their first dose.

continued on page 5 — **COVID-19 vaccinations** >

## Special Announcements

### Promoting technology and safety

ISMP is participating in a new patient safety campaign focusing on how technology can help prevent errors. The campaign includes a supplement in *USA Today* and online articles by globally recognized patient safety leaders. For a feature on smart infusion pump optimization contributed by ISMP's Michelle Mandrack, visit: [www.ismp.org/ext/676](http://www.ismp.org/ext/676). For a copy of ISMP's smart pump guidelines, visit: [www.ismp.org/node/972](http://www.ismp.org/node/972).

### Investigational drug labeling meeting

The US Food and Drug Administration (FDA) will be holding a Public Meeting, *Potential Medication Error Risks with Investigational Drug Container Labels*, on **May 18** (1 p.m. to 4 p.m. ET) and **May 19** (10 a.m. to 1 p.m. ET). FDA is soliciting input from stakeholders (e.g., sponsors, investigators, clinical sites, entities that supply or label investigational drugs, study participants) about the risk of errors related to investigational drug container labels and practices that might minimize the risk of errors. For a tentative meeting agenda, visit: [www.ismp.org/ext/666](http://www.ismp.org/ext/666). In preparation for the meeting, consider reading a two-part article on the challenges posed by investigational drug container labels in our 2018 newsletters by visiting: [www.ismp.org/node/1048](http://www.ismp.org/node/1048) and [www.ismp.org/node/1068](http://www.ismp.org/node/1068).

### Attend ISMP's virtual workshop

Transform the way you manage risk by participating in one of ISMP's virtual *Medication Safety Intensive (MSI)* workshops offered on:

- **June 24-25, 2021** (later start time for Pacific time participants)
- **August 5-6, 2021**

During these 2-day workshops, our faculty will challenge you to see your organization through the eyes of leading safety experts, identify your unique safety challenges, and maximize your error prevention efforts. Upon completion, you will have an invaluable understanding of the infrastructure needed to support ongoing safety improvements. For information or to register, visit: [www.ismp.org/node/127](http://www.ismp.org/node/127).

## &gt; COVID-19 vaccinations — continued from page 4

- Establish a vaccination scheduling system that does not allow patients younger than 16 years to obtain an appointment, and schedules appointments for patients who are 16 and 17 years old only for administration of the Pfizer-BioNTech vaccine.
- During the check-in process:
  - Ask patients age-related screening questions including their date of birth. Strictly comply with vaccine age restrictions.
  - Check the state/local IIS for documentation of a previous COVID-19 vaccine for all patients requesting a first or second vaccine dose. Require all patients who arrive for a second dose to present their vaccine card and have them carry the card throughout the process so the vaccinator can verify the information.

**Preparation process**

- If feasible within the timeframe for vaccine stability at room temperature, have the pharmacy verify the number of vaccines needed each day (to prevent waste) and dispense prefilled, labeled syringes of the vaccine to vaccination clinics.
- In the pharmacy:
  - Stock vials of sterile water in a different location than 0.9% sodium chloride
  - Separate the preparation of each brand of vaccine
  - Withdraw doses from one vaccine vial at a time before accessing the next vial
  - Label vaccine syringes immediately after preparation
- Remove syringes from their packaging one at a time immediately before drawing up diluents or doses; do not open syringe packages ahead of time and/or fill syringes with air in preparation for later dose or diluent withdrawal.

**Administration process**

- Stock each vaccination station with a sharps container for syringe/needle disposal.
- Before administration of any dose, check the syringe for the correct dose volume, air bubbles, and a tight fit between the needle hub and the syringe.
- Before administration of a second dose, visually check the patient's vaccine card to verify the correct time interval and manufacturer.
- If preparing the Pfizer-BioNTech vaccine outside of the pharmacy, require an independent double check of the dilution process (if staffing permits).
- After administration, immediately engage the needle safety device and dispose of the syringe in a sharps container (do not leave the used syringe on the table).
- Report any syringe or needle malfunctions to the pharmacy.
- After administration, complete the patient's vaccine card. For single-dose COVID-19 vaccines, cover all references to a second dose (front and back of the card) with a note that only a single dose is required.
- Stock the vaccination site with **EPINEPH**rine autoinjectors rather than prefilled syringes to visually differentiate **EPINEPH**rine injections from vaccine syringes.

**If an error happens**

- Always inform the patient of a vaccine administration error.
- Visit [www.ismp.org/ext/684](http://www.ismp.org/ext/684) for a table published by the CDC that provides interim recommendations for actions to take after an error has happened.<sup>7</sup>
- Determine how the error occurred and implement strategies to prevent it from happening again.
- Providers are required to report all COVID-19 vaccine administration errors—even those not associated with an adverse event—to the Vaccine Adverse Event Reporting System (VAERS, <https://vaers.hhs.gov>). Also report significant adverse events (including SIRVA) following vaccination, cases of multisystem inflammatory syndrome, and cases of COVID-19 in immunized patients that result in hospitalization or death, even if you are not certain that the vaccination was related to the event.
- Also report COVID-19 vaccination errors to ISMP ([www.ismp.org/report-medication-error](http://www.ismp.org/report-medication-error)) to promote shared learning opportunities.

References appear in the right column &gt;

**References**

- 1) Haseman J. Tracking COVID-19 vaccine distribution by state: how many people have been vaccinated in the US? *USA Today*. January 14, 2021. Updated April 18, 2021. [www.ismp.org/ext/677](http://www.ismp.org/ext/677)
- 2) Centers for Disease Control and Prevention (CDC). Recommendation to pause use of Johnson & Johnson's Janssen COVID-19 vaccine. Updated April 20, 2021. [www.ismp.org/ext/678](http://www.ismp.org/ext/678)
- 3) Oliver S, Shimabukuro T. Johnson & Johnson/Janssen COVID-19 vaccine and cerebral venous sinus thrombosis with thrombocytopenia – update for clinicians on early detection and treatment. Clinical Outreach and Communication Activity (COCA) webinar. April 15, 2021. [www.ismp.org/ext/681](http://www.ismp.org/ext/681)
- 4) European Medicines Agency (EMA). Astra-Zeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Published April 7, 2021. [www.ismp.org/ext/682](http://www.ismp.org/ext/682)
- 5) Institute for Safe Medication Practices (ISMP). Learning from errors with the new COVID-19 vaccines. *ISMP Medication Safety Alert! Acute Care*. 2021;26(1):1-5. [www.ismp.org/node/22009](http://www.ismp.org/node/22009)
- 6) Schillie SF, Buzzell J, Nelson CA, Kidd S, Shealy KR, Reagan-Steiner S. Common COVID vaccine administration errors to watch for. *Medscape*. April 9, 2021. [www.ismp.org/ext/683](http://www.ismp.org/ext/683)
- 7) Centers for Disease Control and Prevention (CDC). COVID-19 vaccine: administration errors and deviations. Published March 17, 2021. [www.ismp.org/ext/684](http://www.ismp.org/ext/684)
- 8) Fernandez L. Thousands at Oakland Coliseum received wrong vaccine dosage, medical staff say. *KTVU Fox 2*. March 3, 2021. [www.ismp.org/ext/685](http://www.ismp.org/ext/685)
- 9) Institute for Safe Medication Practices (ISMP). Vaccine card incorrect for single-dose COVID-19 vaccine. *ISMP Medication Safety Alert! Acute Care*. 2021;26(6):1-2. [www.ismp.org/ext/687](http://www.ismp.org/ext/687)

To subscribe: [www.ismp.org/node/10](http://www.ismp.org/node/10)

**ISMP Medication Safety Alert! Acute Care** (ISSN 1550-6312) © 2021 Institute for Safe Medication Practices

(ISMP). Subscribers are granted permission to redistribute the newsletter or reproduce its contents within their practice site or facility only. Other reproduction, including posting on a public-access website, is prohibited without written permission from ISMP. This is a peer reviewed publication.

**Report medication and vaccine errors to ISMP:** Call 1-800-FAIL-SAF(E) or visit our website at: [www.ismp.org/report-medication-error](http://www.ismp.org/report-medication-error). ISMP guarantees the confidentiality of information received and respects the reporters' wishes regarding the level of detail included in publications.

**Editors:** Judy Smetzer, BSN, RN, FISMP; Michael Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP; Ann Shastay, MSN, RN, AOCN; Russell Jenkins, MD; Ronald S. Litman, DO, ML. ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044. Email: [ismpinfo@ismp.org](mailto:ismpinfo@ismp.org); Tel: 215-947-7797; Fax: 215-914-1492.



# MEDICATION SAFETY CONSULTING SERVICES

## TAILORED TO YOUR NEEDS

The nationally recognized experts at the Institute for Safe Medication Practices (ISMP) are available for focused input and recommendations for organizations of all sizes and most healthcare settings, anywhere in the world. Services range from guidance on one particular topic to a full medication safety risk assessment. Our consultants can help you sort through complex safety issues, identify key next steps, and create a practical path forward to implement evidence-based strategies and best practices.

### ISMP EXPERTS CAN PROVIDE:

- › Consulting support that best fits your situation
- › Assistance building a foundation for your medication safety program
- › Unbiased analysis of ongoing problems and customized guidance
- › Valuable input at the table during key safety discussions and decisions

For more information:

[ismp.org/services/tailored-medication-safety-consulting](https://www.ismp.org/services/tailored-medication-safety-consulting)

